In the BioHarmony Drug Report Database

"Preview" Icon

Alfuzosin

Uroxatral (alfuzosin) is a small molecule pharmaceutical. Alfuzosin was first approved as Uroxatral on 2003-06-12. It is used to treat prostatic hyperplasia in the USA. The pharmaceutical is active against alpha-1B adrenergic receptor, alpha-1D adrenergic receptor, and alpha-1A adrenergic receptor.

 

Trade Name

 

Uroxatral
 

Common Name

 

alfuzosin
 

ChEMBL ID

 

CHEMBL709
 

Indication

 

prostatic hyperplasia
 

Drug Class

 

Image (chem structure or protein)

Alfuzosin structure rendering